The Lancet 1995 345, Post-transfusion hepatitis impact of non-A,non-B hepatitis surrogate tests by M. Blajchman et al. Contains results of a Canadian study indicating that surrogate marker screening has value in reducing infection provided that specific anti-HCV screening is not in place. Contains tables on characteristics of subjects, hepatitis events, and hepatitis by exposure status.